Unternehmen ORIC Pharmaceuticals, Inc. Börse Stuttgart
Aktien
A2P208
US68622P1093
4TZ
Biotechnologie
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
7 EUR | -1.41% | +6.77% | -12.88% |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Jacob Chacko
CEO | Chief Executive Officer | 45 | 07.05.18 |
Richard Heyman
FOU | Founder | 66 | 01.01.14 |
Director of Finance/CFO | 50 | 01.09.19 | |
Lori Friedman
CTO | Chief Tech/Sci/R&D Officer | 60 | 01.07.19 |
Edna Maneval
CTO | Chief Tech/Sci/R&D Officer | 64 | 01.03.19 |
Pratik Multani
CTO | Chief Tech/Sci/R&D Officer | 57 | 01.09.18 |
Dan Iazzetti
HRO | Human Resources Officer | - | 01.09.22 |
Matthew Panuwat
PRN | Corporate Officer/Principal | 47 | 01.11.18 |
General Counsel | 51 | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Angie You
BRD | Director/Board Member | 51 | 09.11.21 |
Richard Heyman
FOU | Founder | 66 | 01.01.14 |
Mardi Dier
BRD | Director/Board Member | 60 | 02.03.20 |
Lori Kunkel
BRD | Director/Board Member | 66 | 09.06.20 |
Jacob Chacko
CEO | Chief Executive Officer | 45 | 07.05.18 |
Steven Hoerter
BRD | Director/Board Member | 53 | 13.08.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 67 422 307 | 60 981 029 ( 90,45 %) | 0 | 90,45 % |
Unternehmenskontakt
Oric Pharmaceuticals, Inc.
240 East Grand Avenue 2nd Floor
94080, South San Francisco
+650 388 5600
http://www.oricpharma.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+16.44% | 122 Mrd. | |
+18.94% | 114 Mrd. | |
+19.62% | 25.71 Mrd. | |
-25.37% | 19.02 Mrd. | |
-20.21% | 15.83 Mrd. | |
-20.20% | 15.32 Mrd. | |
-47.37% | 14.88 Mrd. | |
+59.91% | 14.82 Mrd. | |
+4.35% | 14.1 Mrd. |
- Börse
- Aktien
- A2P208 Aktie
- A2P208 Aktie
- Unternehmen ORIC Pharmaceuticals, Inc.